

Helene Blons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2668919/publications.pdf>

Version: 2024-02-01

18
papers

617
citations

759233

12
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

1300
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. <i>Gynecologic Oncology</i> , 2022, , .	1.4	5
2	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101880.	1.5	1
3	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. <i>Lung Cancer</i> , 2021, 151, 69-75.	2.0	12
4	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4768-4780.	7.0	25
5	Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. <i>British Journal of Cancer</i> , 2021, 125, 1544-1551.	6.4	11
6	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). <i>European Journal of Cancer</i> , 2021, 159, 24-33.	2.8	24
7	High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 237-247.	4.4	3
8	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	3.7	72
9	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	6.1	24
10	Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 405-411.	2.6	9
11	Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. <i>Lung Cancer</i> , 2019, 137, 149-156.	2.0	63
12	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 844-856.	1.1	55
13	Role of circulating tumor DNA in the management of patients with colorectal cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 396-402.	1.5	14
14	Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 550-564.	2.8	30
15	Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma. <i>Neurology</i> , 2018, 91, 523-525.	1.1	19
16	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). <i>Clinical Cancer Research</i> , 2017, 23, 5416-5425.	7.0	189
17	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. <i>Journal of Cancer</i> , 2014, 5, 425-432.	2.5	30
18	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting - IFCT/ERMETIC2 Project Part 1. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 45-55.	2.8	31